 |
 |
I am writing an open letter for the first time since I have started monitoring the Parkinson group area. I am 48 years old and have had pd for about 3 years. I have attended YOPD meetings in the Bay area since my diagnosis under the excellent guidance of Alan Bonander, whom many of you know from this group. I was initially excited by the recent report about NADH therapy that was presented here June 30. However, my excitement was quickly dashed when I read the attached article from the Scandinavian J of Neurology, which suggests that in their placebo-controlled study of 10 patients (5 NADH treated, 5 placebo) that all 10 patients improved and that there was no additional efficacy of NADH. Only a large, randomized study will prove this one way or the other. Meanwhile, I will read with some skepticism non-placebo-controlled testimonials such as that provided by Dr. Atkins. Since I have a high degree of respect for the competence and intellectual honesty of most of the people on this list, I look forward to your comments. Respectfully, John Wherry ([log in to unmask]) Dizdar N, K~agedal B, Lindvall B Treatment of **Parkinson's** **disease** with **NADH.** Department of Neurology, University Hospital, Linkoping, Sweden. Acta Neurol Scand 1994 Nov;90(5):345-7 Article Number: UI95193491 ABSTRACT: It has earlier been claimed that clinical improvement of patients with **Parkinson's** **disease** is obtained by treatment with **NADH.** This has to be verified by double-blind, clinical studies and measurement of biochemical effects of the treatment. In a double blind study five patients with clinically moderate **Parkinson's** **disease** were treated with **NADH,** 25 mg, given intravenously once a day for four days. Then they were given 25 mg **NADH** intramuscularly after 2 and 4 weeks. Disability scores were determined before each treatment and two weeks after the final injection. A control group (n = 4) with the same degree of **Parkinson's** **disease** obtained sodium chloride with the same schedule. According to the Unified **Parkinson's** **Disease** Rating Scale a tendency to clinical improvement was seen after the iv infusions in both treatment and placebo groups. However, the changes were not statistically significant, and no changes occurred during the following weeks. No changes were found neither in the study nor the control group regarding cerebrospinal fluid concentrations of dynorfin, metenkefalin, somatostatin, hydroxy-methoxy-phenylglycol, homovanillic acid and 5-hydroxyindole acetic acid. The results indicate that no great changes are obtained after short-term treatment of parkinsonian patients with **NADH,** neither clinically nor biochemically.